Figure 4.

Dosing schedule, safety, and tissue distribution of Me₂SPM in vivo. C57Bl/6J mice (n = 24) were treated for 4 days with increasing doses of Me₂SPM (0 mg/kg, n = 7; 5 mg/kg, n = 2; 10 mg/kg, n = 7; 50 mg/kg, n = 6; 100 mg/kg, n = 2). Changes in body mass and timing of intraperitoneal injections are indicated by arrows in Fig. 4A. Tissues were collected for enzyme activity assays and HPLC analysis of polyamine and Me₂SPM concentrations on day 4 (0, 5, and 10 mg/kg groups) or day 3 (50 and 100 mg/kg groups). Tissue concentrations of Me₂SPM relative to total protein in the mock, 10, and 50 mg/kg groups are shown in B, with individual mice plotted as circles and the means and S.E. of each group indicated with horizontal lines and error bars.